GRI Bio GRI 深 滬
已收盤 08-07 16:00:00 美东时间
1.47
-0.080
-5.16%
華盛通- 最 高1.55
- 今 開1.55
- 成交量 3.27万股
- 最 低 1.41
- 昨 收 1.55
- 總市值 260.31万
- 52周最高 80.36
- 市盈率 靜 --
- 換手率 1.84%
- 52周最低 1.36
- 委 比 -40.00%
- 總股本 177.08万
- 歷史最高 64792072.80
- 量 比 1.27
- 振 幅 9.03%
- 歷史最低 1.41
- 每 手 1
- 風險率 22.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多GRI Bio Says FDA Grants Orphan Drug Designation To GRI-0621 For Treatment Of Idiopathic Pulmonary Fibrosis, Irreversible And Ultimately Fatal Lung Disease
Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity LA JOLLA, CA, June 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company developing innovative therapies for infl...
06-18 20:34
美股大行评级 | 瑞杰金融上调美光目标价从530美元升至1100美元；AMD、Arm、戴尔、英特尔等获多家机构上调目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13.5美元升至14美元；BTIG：维持Jade Biosciences"买入"评级，目标价从39美元升至74美元
06-02 16:25
Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know
Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price targets raised/cut, ratings maintained/changed.
06-01 20:43
Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $32
Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and lowers the price target from $40 to $32.
06-01 18:28
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
GRI Bio, Inc. announced that its CEO, Marc Hertz, PhD, will participate in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase on May 20, 2026. The event will discuss the company’s immune-modulating pipeline targeting inflammatory, fibrotic, and autoimmune diseases, including its lead program, GRI-0621, for idiopathic pulmonary fibrosis. A live webcast will be available on the company’s website.
05-18 13:15
GRI Bio发布Q1财报 特发性肺纤维化新药数据积极
财务表现：亏损收窄，现金储备增强 GRI Bio近日公布2026年第一季度财务报告。数据显示，公司一季度净亏损约200万美元，较上年同期的300万美元亏...
05-15 02:50
GRI Bio reports Q1 results
GRI Bio press release (GRI): Q1 Net loss for the quarter ended March 31, 2026, was approximately $2.0 million, compared to approximately $3.0 million for the same period in 2025 Cash and cash equivale...
05-15 02:31
GRI Bio Q1 EPS $(1.61) Misses $(0.91) Estimate
GRI Bio (NASDAQ:GRI) reported quarterly losses of $(1.61) per share which missed the analyst consensus estimate of $(0.91) by 78.89 percent. This is a 99.01 percent increase over losses of $(162.40) per share from the
05-14 20:45
